MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced a new 24-sample option for its highly acclaimed GlycoWorks™ RapiFluor-MS™ N-Glycan Kit. The new format processes 24 samples - eight at a time - and opens the door further to laboratories that want to begin realizing the benefits that RapiFluor-MS brings to glycan analysis.
Depending on a laboratory’s sample preparation needs, the Waters® GlycoWorks RapiFluor-MS N-Glycan Kit is now available in either a 24-sample or 96-sample format. The RapiFluor-MS labelling reagent yields enhanced MS sensitivity that is 100 to 1,000-fold greater than current approaches. It also supports a simple, robust protocol for routine laboratory use that incorporates the ACQUITY® QDa® mass detector.
For More Information
With the RapiFluor-MS N-Glycan Kit, laboratories are developing one-hour deglycosylation and labeling methods that once took 24 hours or more. This video describes how one of those laboratories completely transformed their monoclonal antibody glycoprofiling methodology.
For more information about the GlycoWorks RapiFluor-MS N-Glycan Kit, visit www.waters.com/glycans.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT) develops and manufactures advanced analytical and material science technologies for laboratory dependent organizations. For more than 50 years, the company has pioneered a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis systems.
Waters, ACQUITY, QDa, GlycoWorks, and RapiFluor-MS are trademarks of Waters Corporation.